PFE analyst scorecard · Pfizer
29 rating changes on PFE in the last 12 months. 54% of bullish calls were right at 30 days; 50% of bearish ones. Street grade C on 17 scored calls. Consensus target $29, 4% above the last close.
Graded through 2026-09-14 · last close $27.75 (2026-09-14). Rebuilt every morning.
Holds on PFE, read: 2 cut to or raised to Hold (graded as the change) · 3 Holds whose target leaned 10%+ one way (graded that way) · 12 true Holds, not graded.
Firm by firm
| Firm | Calls | Scored | Right | Accuracy | Grade | Avg 30d | Avg 90d | Latest | Date | Target |
|---|---|---|---|---|---|---|---|---|---|---|
| Guggenheim | 4 | 4 | 2 | 50.0% | C | +2.4% | +0.2% | Buy | 2026-08-07 | $31 |
| Cantor Fitzgerald | 3 | 1 | 1 | — | — | +4.0% | -0.1% | Neutral | 2026-07-06 | $27 |
| BMO Capital | 1 | 1 | 1 | — | — | +7.5% | — | Outperform | 2026-07-13 | $30 |
| JPMorgan | 1 | 1 | 1 | — | — | +11.3% | — | Neutral | 2026-07-08 | $28 |
| Argus Research | 1 | 1 | 1 | — | — | +4.7% | -6.0% | Buy | 2026-03-02 | $35 |
| Freedom Broker | 1 | 1 | 1 | — | — | +0.9% | -4.6% | Buy | 2026-02-09 | $33 |
| RBC Capital | 3 | 3 | 2 | — | — | -4.0% | -2.0% | Sector Perform | 2026-06-10 | $25 |
| Bank of America | 4 | 0 | 0 | — | — | -1.6% | -6.3% | Neutral | 2026-07-10 | $26 |
| Morgan Stanley | 4 | 1 | 0 | — | — | -1.4% | +1.4% | Equal-Weight | 2026-04-10 | $28 |
| HSBC | 3 | 2 | 0 | — | — | +4.0% | -5.3% | Hold | 2026-09-10 | $30 |
| Citigroup | 1 | 0 | 0 | — | — | -0.3% | -3.9% | Neutral | 2026-04-29 | $27 |
| CICC | 1 | 1 | 0 | — | — | -6.9% | -8.8% | Outperform | 2026-04-16 | $33 |
| UBS | 1 | 0 | 0 | — | — | -5.0% | -10.5% | Neutral | 2026-04-13 | $27 |
| Barclays | 1 | 1 | 0 | — | — | +0.5% | -2.6% | Underweight | 2026-02-20 | $25 |
Dimmed rows have fewer than 4 scored calls on PFE — too few to grade.
Every call, last 12 months
| Date | Firm | Change | Action | Graded as | Price at call | Run before | +30d | +60d | +90d | Target · 90d check | Hit |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-10 | HSBC | Hold → Hold | maintained | True hold · target +8% | $27.65 | +3.9% | — | — | — | $30 | not graded |
| 2026-08-07 | Guggenheim | Buy → Buy | maintained | Bullish | $26.76 | +11.3% | +3.9% | — | — | $31 | ✓ |
| 2026-07-13 | BMO Capital | Outperform → Outperform | maintained | Bullish | $24.48 | -6.6% | +7.5% | +13.2% | — | $30 | ✓ |
| 2026-07-13 | Guggenheim | Buy → Buy | maintained | Bullish | $24.48 | -6.6% | +7.5% | +13.2% | — | $35 | ✓ |
| 2026-07-10 | Bank of America | Neutral → Neutral | maintained | True hold · target +7% | $24.17 | -5.6% | +11.9% | +15.0% | — | $26 | not graded |
| 2026-07-08 | JPMorgan | Neutral → Neutral | maintained | Leans bullish · Neutral, target +16% | $24.05 | -6.1% | +11.3% | +15.6% | — | $28 | ✓ |
| 2026-07-06 | Cantor Fitzgerald | Neutral → Neutral | reiterated | Leans bullish · Neutral, target +13% | $23.72 | -8.9% | +8.8% | +19.9% | — | $27 | ✓ |
| 2026-07-06 | HSBC | Buy → Hold | downgrade | Bearish · cut to Hold | $23.72 | -8.9% | +8.8% | +19.9% | — | $28 | ✗ |
| 2026-06-10 | RBC Capital | Underperform → Sector Perform | upgrade | Bullish · raised to Sector Perform | $25.60 | -0.8% | -5.6% | +5.7% | +8.6% | $25 missed | ✗ |
| 2026-04-29 | Citigroup | Neutral → Neutral | maintained | True hold · target +2% | $26.26 | -5.4% | -0.3% | -7.2% | -3.9% | $27 missed | not graded |
| 2026-04-20 | RBC Capital | Underperform → Underperform | reiterated | Bearish | $27.52 | +2.0% | -6.3% | -8.9% | -10.1% | $25 hit | ✓ |
| 2026-04-16 | CICC | Outperform | initiated | Bullish | $27.22 | -0.8% | -6.9% | -4.5% | -8.8% | $33 missed | ✗ |
| 2026-04-13 | UBS | Neutral → Neutral | maintained | True hold · target -1% | $27.34 | +2.9% | -5.0% | -4.1% | -10.5% | $27 missed | not graded |
| 2026-04-10 | Morgan Stanley | Equal-Weight → Equal-Weight | maintained | True hold · target +4% | $26.92 | -1.4% | -4.1% | -4.5% | -9.9% | $28 missed | not graded |
| 2026-04-09 | Bank of America | Neutral → Neutral | maintained | True hold · target -4% | $27.22 | +0.2% | -5.2% | -5.9% | -11.7% | $26 hit | not graded |
| 2026-03-24 | Guggenheim | Buy → Buy | maintained | Bullish | $26.96 | +1.2% | -1.1% | -4.1% | -7.0% | $36 missed | ✗ |
| 2026-03-17 | HSBC | Buy → Buy | maintained | Bullish | $27.45 | -0.5% | -0.8% | -7.7% | -5.3% | $32 missed | ✗ |
| 2026-03-02 | Argus Research | Hold → Buy | upgrade | Bullish | $27.26 | +3.1% | +4.7% | -3.4% | -6.0% | $35 missed | ✓ |
| 2026-02-25 | RBC Capital | Underperform | initiated | Bearish | $27.09 | +4.7% | -0.2% | -1.1% | -4.6% | $25 hit | ✓ |
| 2026-02-20 | Barclays | Underweight | initiated | Bearish | $26.65 | +2.9% | +0.5% | +2.5% | -2.6% | $25 hit | ✗ |
| 2026-02-09 | Freedom Broker | Buy → Buy | maintained | Bullish | $27.05 | +6.2% | +0.9% | -0.5% | -4.6% | $33 missed | ✓ |
| 2026-02-04 | Cantor Fitzgerald | Neutral → Neutral | reiterated | True hold · target +0% | $26.78 | +6.4% | +1.0% | +3.9% | -1.2% | $27 hit | not graded |
| 2026-01-27 | Cantor Fitzgerald | Neutral → Neutral | maintained | True hold · target +1% | $26.50 | +5.6% | +2.3% | +4.8% | +1.1% | $27 hit | not graded |
| 2025-12-17 | Morgan Stanley | Equal-Weight → Equal-Weight | maintained | True hold · target +7% | $25.04 | -0.2% | +2.4% | +9.3% | +9.6% | $27 hit | not graded |
| 2025-12-15 | Bank of America | Neutral → Neutral | maintained | True hold · target +5% | $26.43 | +5.5% | -3.2% | +4.3% | +0.7% | $28 hit | not graded |
| 2025-12-12 | Morgan Stanley | Equal-Weight → Equal-Weight | maintained | True hold · target +8% | $25.85 | -0.1% | -2.2% | +6.8% | +3.9% | $28 hit | not graded |
| 2025-11-24 | Guggenheim | Buy → Buy | maintained | Bullish | $25.22 | +1.9% | -0.8% | +1.7% | +7.3% | $35 missed | ✗ |
| 2025-10-10 | Morgan Stanley | Equal-Weight → Equal-Weight | maintained | Leans bullish · Equal-Weight, target +29% | $24.78 | — | -1.6% | +2.2% | +2.1% | $32 missed | ✗ |
| 2025-10-03 | Bank of America | Neutral → Neutral | maintained | True hold · target +9% | $27.37 | — | -9.9% | -8.1% | -8.0% | $30 missed | not graded |
Also in Pharma
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How the grading works
Every sell-side rating change from the last 365 days is priced the day it lands and checked again 30, 60 and 90 days later. A call is a hit when the stock moved in the called direction at 30 days. Buy- and Sell-side ratings call their own direction. A Hold is read, not waved through: a downgrade to Hold is graded as a bearish call and an upgrade to Hold as a bullish one, and a maintained Hold whose price target sits 10%+ above the price leans bullish (10%+ below, leans bearish) and is graded that way. A Hold with a target close to the price is a true Hold and is not graded at all. Every call with a price target also gets a target check 90 days later: hit (reached it or within 5%), close (covered at least half the distance) or missed. A firm's accuracy on a single name prints only after 4 scored calls, and a firm gets its own page only after 10 scored calls across every covered name — below that a percentage is noise. "Run before the call" is the stock's move over the 30 calendar days before the rating landed. Data: Yahoo Finance rating history and daily closes, rebuilt each morning. Nothing on this page is advice.
Get the 7 AM brief
The AM take, today's docket and the Street's calls — one email, weekdays, before the open.